NCT07466394 · RECRUITING
COGSCREEN II: Early Detection of Cognitive Impairment
COGSCREEN II is testing whether a structured screening program using digital cognitive tests and blood-based biomarkers can reliably identify early cognitive decline in people aged 60 and older through regular GP and specialist practices in Germany. This is a Phase NA behavioral study, meaning it is evaluating a detection system rather than a drug. It aims to find people with subtle memory concerns before dementia is diagnosed.
You may qualify if
- Male or female ≥ 60 years of age at the time of consent
- Able to understand and voluntarily sign an informed consent according to the judgment of the practice team
You're excluded if
- Subjects who are unable to hear or see well enough to complete the assessments
- Prior diagnosis of dementia (with or without evidence of pathology) as documented in the medical record and/or diagnosed by a physician
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-12